ArticleClinical proteomics2010
Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.
Article in Clinical proteomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Trial
- Clinical Peptidomics in Acute Leukemias: Current Advances and Future Perspectives.Journal of proteome research · 2024Review
- Altered molecular pathways and prognostic markers in active systemic juvenile idiopathic arthritis: integrated bioinformatic analysis.Bosnian journal of basic medical sciences · 2022Article
- Developing mass spectrometry for the quantitative analysis of neuropeptides.Expert review of proteomics · 2021Review
- Extracellular peptide Kratos restricts cell death during vascular development and stress in Arabidopsis.Journal of experimental botany · 2019Article
- Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.Immunogenetics · 2019Review
- The Antigen Processing and Presentation Machinery in Lymphatic Endothelial Cells.Frontiers in immunology · 2019Review
- Proteomics in Chronic Arthritis-Will We Finally Have Useful Biomarkers?Current rheumatology reports · 2018Review
- Enhancing translational research in paediatric rheumatology through standardization.Nature reviews. Rheumatology · 2016Review
- The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity.The Journal of biological chemistry · 2016Article
- Autoimmune response to transthyretin in juvenile idiopathic arthritis.JCI insight · 2016Article
- Serological targeted analysis of an ITIH4 peptide isoform: a preterm birth biomarker and its associated SNP implications.Journal of genetics and genomics = Yi chuan xue bao · 2015Article
- Advances in biomarkers for paediatric rheumatic diseases.Nature reviews. Rheumatology · 2015Review
- Current peptidomics: applications, purification, identification, quantification, and functional analysis.Proteomics · 2015Review
- Current developments in the use of biomarkers for juvenile idiopathic arthritis.Current rheumatology reports · 2014Review
- Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.Clinical proteomics · 2014Article
- Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B.Journal of translational medicine · 2013Article
- Article
- Correlation analyses of clinical and molecular findings identify candidate biological pathways in systemic juvenile idiopathic arthritis.BMC medicine · 2012Article
- A diagnostic algorithm combining clinical and molecular data distinguishes Kawasaki disease from other febrile illnesses.BMC medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
purposeSystemic juvenile idiopathic arthritis is a chronic pediatric disease. The initial clinical presentation can mimic other pediatric inflammatory conditions, which often leads to significant delays in diagnosis and appropriate therapy. SJIA biomarker development is an unmet diagnostic/prognostic need to prevent disease complications. EXPERIMENTAL
designWe profiled the urine peptidome to analyze a set of 102 urine samples, from patients with SJIA, Kawasaki disease (KD), febrile illnesses (FI), and healthy controls. A set of 91 plasma samples, from SJIA flare and quiescent patients, were profiled using a customized antibody array against 43 proteins known to be involved in inflammatory and protein catabolic processes.
resultsWe identified a 17-urine-peptide biomarker panel that could effectively discriminate SJIA patients at active, quiescent, and remission disease states, and patients with active SJIA from confounding conditions including KD and FI. Targeted sequencing of these peptides revealed that they fall into several tight clusters from seven different proteins, suggesting disease-specific proteolytic activities. The antibody array plasma profiling identified an SJIA plasma flare signature consisting of tissue inhibitor of metalloproteinase-1 (TIMP1), interleukin (IL)-18, regulated upon activation, normal T cell expressed and secreted (RANTES), P-Selectin, MMP9, and L-Selectin. CONCLUSIONS AND CLINICAL RELEVANCE: The urine peptidomic and plasma protein analyses have the potential to improve SJIA care and suggest that SJIA urine peptide biomarkers may be an outcome of inflammation-driven effects on catabolic pathways operating at multiple sites. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12014-010-9058-8) contains supplementary material, which is available to authorized users.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.